You Can Influence ICER Recommendations, You Just Need the Right Evidence

  It’s difficult to dispute the findings of an advisory group which is widely accepted as the authority, especially when it comes to evaluating the value of different therapeutic interventions. The cost of drugs in the US has been a hot button topic in recent years, so healthcare industry stakeholders are increasingly looking for objective […]

BHE is Now Panalgo: Why We Changed Our Name and Brand

In 1996, I started Boston Health Economics (BHE) to provide professional research services to the life sciences industry, including economic modeling, database analyses and strategic consulting. For more than two decades we have had the privilege of serving the industry’s leading life sciences organizations. When my son, Jordan, joined the company in 2010, his work […]

ICER’s Development and Use of RWE: 5 Areas for Concern

The pervasiveness of real-world data (RWD) and the need to understand outcomes in clinical practice have galvanized the ubiquity and utility of real-world evidence (RWE). Especially within the life sciences industry, RWE is increasingly leveraged by research and development, epidemiology, outcomes research, and commercial groups across an asset’s lifecycle to strengthen product evidence and value […]

BHE Holds Annual User Conference for its Instant Health Data (IHD) Platform

BHE hosted its annual Instant Health Data (IHD) User Conference on March 20, 2019 at the Four Seasons Hotel in Boston, Massachusetts. This day-long event brought together IHD users and analytics team leads from 20 top-ranked pharmaceutical companies, medical device manufacturers, and research organizations. Presenters offered in-depth experiences on the adoption of the IHD platform […]